Andrew Scaife, Chief Executive Officer of Quantum Pharma Plc (LON:QP.), said: “The first six months of the financial year have been a busy period at Quantum Pharma. We successfully completed the strategic acquisitions of Lamda and NuPharm and the integration of both these companies into the Group is ongoing. In addition, pleasingly, a number of the business units have had record half years.
Progress continues to be made on the Colonis pipeline, and we look forward to announcing a number of further regulated product launches during the second half of the year. As is sometimes the case, the regulatory process on certain products is taking slightly longer than anticipated, however we are confident of securing licences for all products in assessment with the MHRA and other regulators. We look forward to presenting our half year results in October.”
Quantum Pharma Plc (AIM: QP.), the growing service-led niche pharmaceutical manufacturer, developer and supplier to the health and care sectors, has given DirectorsTalk its pre-close trading update for the half year ended 31 July 2015.
The Board has said that Quantum has made good strategic progress across all areas of its business in the last six months. Trading for the Group remains in line with market expectations for the year to 31 January 2016.
As previously announced Quantum completed the acquisitions of the Lamda group of companies and NuPharm Group during this period. The Board is confident that these businesses will add value to the Group in the future.
Colonis, the specialist pharmaceutical product development business, continues to grow its pipeline and submissions to the relevant authorities and to progress its product launch programme:
— over 70 regulated products (licensed products and medical devices) are now in the pipeline with a number of other opportunities to increase the pipeline further during this financial year (May 2015: 60 regulated products).
— 16 products are in for assessment with the MHRA and other authorities for registration. That number is expected to be at least 28 by the end of this financial year.
— two products have been launched in the market (one licensed product and one medical device). The second licensed product is manufactured and awaiting final release permission from the MHRA to enter the market. It is anticipated that this will be received by the end of September.
— 11 regulated products are expected to have been launched by the end of the financial year. There are also a number of active opportunities for additional regulated products to be brought into the pipeline and launched this year.
The Board remains confident that licences will be achieved for all products submitted for assessment to the relevant regulators although, in respect of a small number of applications made earlier in the year, this is taking longer than expected.
Quantum will announce its half year results for the six months ended 31 July 2015 on Tuesday 20 October 2015.
